(Q28193016)

Journal of Diabetes and its Complications

PubMed

published in

0 references

volume

16

0 references

page(s)

235-45

0 references

issue

3

0 references

cites work

Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Stroke in the diabetic patient

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Diabetes mellitus: a hypercoagulable state

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Interactions between endothelial mediators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Diabetes and decline in heart disease mortality in US adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Diabetes, hyperlipidemia, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Reduced microvascular hyperaemia in subjects at risk of developing type 2 (non-insulin-dependent) diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Microvascular function in type 2 (non-insulin-dependent) diabetes: improved vasodilation after one year of good glycaemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

The demographics of claudication and the aging of the American population

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Effect of strenuous exercise on platelet activation state and reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Altered membrane fatty acid composition and increased thromboxane A2 generation in platelets from patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Heart disease in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Cardiovascular mortality and morbidity in type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

The antiplatelet effects of ticlopidine and clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

The effect of glycemic control on the incidence of macrovascular complications of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused treatments could save thousands of lives

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

ABC of arterial and vascular disease. Secondary prevention of peripheral vascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Platelet dysfunction in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Small fiber neuropathy and neurovascular disturbances in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Diabetic neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Diabetes mellitus and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Dipyridamole plus aspirin in cerebrovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021

Platelet abnormalities in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900212-4

7 January 2021